PubMed Journals Articles About "Neos Therapeutics Controlled Release ADHD Drug Approval" RSS

07:38 EDT 18th March 2018 | BioPortfolio

Neos Therapeutics Controlled Release ADHD Drug Approval PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Neos Therapeutics Controlled Release ADHD Drug Approval articles that have been published worldwide.

More Information about "Neos Therapeutics Controlled Release ADHD Drug Approval" on BioPortfolio

We have published hundreds of Neos Therapeutics Controlled Release ADHD Drug Approval news stories on BioPortfolio along with dozens of Neos Therapeutics Controlled Release ADHD Drug Approval Clinical Trials and PubMed Articles about Neos Therapeutics Controlled Release ADHD Drug Approval for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Neos Therapeutics Controlled Release ADHD Drug Approval Companies in our database. You can also find out about relevant Neos Therapeutics Controlled Release ADHD Drug Approval Drugs and Medications on this site too.

Showing "Neos Therapeutics Controlled Release ADHD Drug Approval" PubMed Articles 1–25 of 18,000+

Defining drug and target protein distributions after stent-based drug release: Durable versus deployable coatings.

Innovations in drug eluting stent designs make it increasingly important to develop models for differentiating performance through spatial definition of drug, receptor binding and cell state.

Polymeric gels for intravaginal drug delivery.

Intravaginal drug delivery can elicit a local effect, or deliver drugs systemically without hepatic first pass metabolism. There are a number of emerging areas in intravaginal drug delivery, but the vagina is a challenging route of administration, due to the clearance mechanisms present which result in poor retention of dosage forms, and the potential for irritation and other adverse reactions. Gel formulations are desirable due to the ease of application, spreading and that they cause little to no discomfo...

Drug delivery systems functionalized with bone mineral seeking agents for bone targeted therapeutics.

The systemic administration of drugs to treat bone diseases is often associated with poor uptake of the drug in the targeted tissue, potential systemic toxicity and suboptimal efficacy. In order to overcome these limitations, many micro- and nano-sized drug carriers have been developed for the treatment of bone pathologies that exhibit specific affinity for bone. Drug carriers can be functionalized with bone mineral seekers (BMS), creating a targeted drug delivery system (DDS) which is able to bind to bone ...

Extracellular vesicle therapeutics for liver disease.

Extracellular vesicles (EVs) are endogenous nanoparticles that play important roles in intercellular communication. Unmodified and engineered EVs can be utilized for therapeutic purposes. For instance, mesenchymal stem cell (MSC)-derived EVs have shown promise for tissue repair, while drug-loaded EVs have the potential to be used for cancer treatment. The liver is an ideal target for EV therapy due to the intrinsic regenerative capacity of hepatic tissue and the tropism of systemically injected nanovesicles...

Light-switchable systems for remotely controlled drug delivery.

Light-switchable systems have recently received attention as a new mode of remotely controlled drug delivery. In the past, a multitude of nanomedicine studies have sought to enhance the specificity of drug delivery to target sites by focusing on receptors overexpressed on malignant cells or environmental features of diseases sites. Despite these immense efforts, however, there are few clinically available nanomedicines. We need a paradigm shift in drug delivery. One strategy that may overcome the limitation...

ADHD medication use in pregnancy and risk of congenital malformation.

Extended-Release ADHD Drug.

Exosome is a mechanism of intercellular drug transfer: Application of quantitative pharmacology.

Exosomes are small membrane vesicles (30-100nm in diameter) secreted by cells into extracellular space. The present study evaluated the effect of chemotherapeutic agents on exosome production and/or release, and quantified the contribution of exosomes to intercellular drug transfer and pharmacodynamics.

Light-Activatable Theranostic Agents for Image-Monitored Controlled Drug Delivery.

A novel drug delivery vehicle using nanodroplets activated by light irradiation for drug release in a controlled manner has been developed. Drug encapsulated in the nanodroplets was released upon the phase-transition from liquid droplet-to-microbubbles (vaporization) by plasmonic photothermal heat from gold nanorods adsorbed on the surface of the nanodroplets. The nanodroplets were stable against aggregation and dissolution at 4 ºC over 3 months to date. The phase-transition was quantitatively analyzed by ...

Controlled release of a hydrophilic drug from electrospun amyloid-like protein blend nanofibers.

In this study, a controlled drug release platform, amyloid-like bovine serum albumin (AL-BSA) with ampicillin sodium salt (amp), was developed. To develop this platform, 5%, 10%, and 20% (w/w) ratios of amp:BSA were used with electrospinning to prepare nanofibers with average diameters of 132±69, 159±60, and 179±42nm, respectively. Fourier transform infrared spectroscopy demonstrated that AL-BSA could entrap large amounts of drug inside the nanofibers, which was attributed to the antimicrobial activity o...

Childhood ADHD Symptoms and Future Illicit Drug Use: The Role of Adolescent Cigarette Use.

The aim of this study is to understand how early cigarette use might predict subsequent illicit drug use, especially among individuals with attention-deficit hyperactivity disorder (ADHD) symptoms during childhood. Data were drawn from the National Longitudinal Study of Adolescent Health (Waves I-IV). The analysis sample involves participants who had not used illicit drugs at Wave I, with no missing responses for studied predictors ( N  = 7,332). Smoking status at Wave I (ever regular vs. never regular)...

Exploring longitudinal course and treatment-baseline severity interactions in secondary outcomes of smoking cessation treatment in individuals with attention-deficit hyperactivity disorder.

A double blind, placebo-controlled randomized trial (NCT00253747) evaluating osmotic-release oral system methylphenidate (OROS-MPH) for smoking-cessation revealed a significant interaction effect in which participants with higher baseline ADHD severity had better abstinence outcomes with OROS-MPH while participants with lower baseline ADHD severity had worse outcomes.

Highly cell-penetrating and ultra-pH-responsive nanoplatform for controlled drug release and enhanced tumor therapy.

A stimuli-triggered drug release strategy could considerably reduce side effects while improving the bioavailability of chemotherapeutics. Here, we report that a series of ultra-pH-responsive copolymers are highly efficient drug delivery systems for near-infrared (NIR) imaging and controlled drug release. These polymers self-assemble into nano-sized micelles due to their amphipathic structure and deliver hydrophobic drugs (maximum drug loading rate ∼10wt%) into tumor cells via a controlled and pH-triggere...

A photosensitive liposome with NIR light triggered doxorubicin release as a combined photodynamic-chemo therapy system.

The targeted drug delivery with the help of nanocarriers and the controlled drug release at the lesion sites are the most effective ways to enhance therapeutic efficacy and reduce side effects. Here, we built a light sensitive liposome (Her2-I&D-LSL) which was formed by a special phospholipid (PLsPC) and a hydrophobically modified photosensitizer (ICG-ODA). DOX was employed as the therapeutic drug, encapsulating in the internal phase of the liposome whose surface was modified by Her2 antibodies for recogniz...

Preparation of Controlled-Release Particles Based on Spherical Porous Silica Used as the Drug Carrier by the Dry Coating Method.

A controlled-release formulation is a dosage form that could improve a patient's quality of life by reducing the frequency of administration, while ensuring the continued effect of the medicine and reducing the side effects. To prepare these controlled-release particles, a wet coating method in which a drug is coated with a controlled-release material using water or an organic solvent is used, but with this method, the coating process is very time-consuming and requires large amounts of energy for the dryin...

Unsaturated nitrogen-rich polymer poly(L-histidine) gated reversibly switchable mesoporous silica nanoparticles using "graft to" strategy for drug controlled release.

A novel and intelligent pH-controlled system having an "on-off" switch based on poly(L-histidine) (PLH) and poly(ethylene glycol) (PEG) coated mesoporous silica nanoparticles (MSNs) (MSNs-PLH-PEG) was designed and evaluated for tumor specific drug release. The unsaturated nitrogen-rich polymer, PLH, which can change its solubility at different pH values, was employed for establishing the reversible "on-off" switch. In vitro drug release results demonstrated that MSNs-PLH-PEG has a pH-controlled "on-off" pro...

Do parental ADHD symptoms reduce the efficacy of parent training for preschool ADHD? A secondary analysis of a randomized controlled trial.

Previous studies have suggested that children with Attention-Deficit/Hyperactivity Disorder (ADHD) may benefit less from behavioral parent training (BPT) if their parents have high levels of ADHD symptoms. We conducted a secondary analysis of data from a randomized controlled trial to test the hypothesis that parental ADHD symptoms reduce the efficacy of two BPT programs in a sample of preschoolers with ADHD. One intervention was specifically designed for children with ADHD (NFPP: New Forest Parenting Progr...

Is patient exposure preapproval and postapproval a determinant of the timing and frequency of occurrence of safety issues?

The amount of drug exposure, pre and post approval, is considered to be a direct determinant of knowledge about the safety of a drug. A larger pre-approval exposed population is supposed to reduce the risk of unanticipated safety issues post-approval. The amount of use in the postapproval population is also expected to influence the occurrence and timing of safety issues. We investigated how the amount of pre and post approval exposure influences the detection of post-approval safety issues.

γ-Irradiated chitosan based injectable hydrogels for controlled release of drug (Montelukast sodium).

Novel pH-sensitive γ-irradiated low molecular weight chitosan (CS) (pre-irradiated) and poly (vinyl alcohol) (PVA) blended injectable hydrogels, crosslinked with varying concentrations of glycerol, were fabricated for drug delivery application. The effect of low molecular weight irradiated CS on controlled drug release was evaluated to address the problem of higher viscosity and lower solubility of high molecular weight CS. The FTIR spectra of hydrogels depicted the presence of all the incorporated functio...

Formation of protein corona in vivo affects drug release from temperature-sensitive liposomes.

Thermally triggered drug release from temperature-sensitive liposomes (TSL) holds great promise for cancer therapy. Different types of TSL have been designed recently for heat triggered drug release inside tumor blood vessels or after accumulation into the tumor interstitium. However, justification of drug release profiles was mainly based on in vitro release data. While these methods could be good enough to give early indication about the thermal sensitivity of TSL, they are still far from being optimum. T...

From concept to in vivo testing: Microcontainers for oral drug delivery.

This work explores the potential of polymeric micrometer sized devices (microcontainers) as oral drug delivery systems (DDS). Arrays of detachable microcontainers (D-MCs) were fabricated on a sacrificial layer to improve the handling and facilitate the collection of individual D-MCs. A model drug, ketoprofen, was loaded into the microcontainers using supercritical CO2 impregnation, followed by deposition of an enteric coating to protect the drug from the harsh gastric environment and to provide a fast relea...

PVP VA64 as a novel release-modifier for sustained-release mini-matrices prepared via hot melt extrusion.

The purpose of this study was to explore poly(vinylpyrrolidone-co-vinyl acetate) (PVP VA64) as a novel release-modifier to tailor the drug release from ethylcellulose (EC)-based mini-matrices prepared via hot melt extrusion (HME). Quetiapine fumarate (QF) was selected as model drug. QF/EC/PVP VA64 mini-matrices were extruded with 30% drug loading. The physical state of QF in extruded mini-matrices was characterized using differential scanning calorimetry, X-ray powder diffraction, and confocal Raman microsc...

Methods for delivering the UK's multi-centre prison-based naloxone-on-release pilot randomised trial (N-ALIVE): Europe's largest prison-based randomised controlled trial.

Naloxone is an opioid antagonist used for emergency resuscitation following opioid overdose. Prisoners with a history of heroin use by injection have a high risk of drug-related death in the first weeks after prison-release. The N-ALIVE trial was planned as a large prison-based randomised controlled trial (RCT) to test the effectiveness of naloxone-on-release in the prevention of fatal opiate overdoses soon after release. The N-ALIVE pilot trial was conducted to test the main trial's assumptions on recruitm...

Construction of multifunctional porous silica nanocarriers for pH/enzyme-responsive drug release.

pH/enzyme-responsive nanocarriers based on porous silica (pSiO2) nanospheres (NSs) were developed for controlled release of drug. The pSiO2 NSs present uniform spheres and have an average diameter of 100nm. The pSiO2 NSs with high specific surface area (835m(2)·g(-1)) and the pore volume (1.24cm(3)·g(-1)) are suitable for drug loading and the loading capacity reaches to 29% for amoxicillin (AMX) model drug. In this system, protocatechuic acid (PCA) and L-glutamic acid (Glu) as linkers were grafting onto t...

A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review.

Accelerated approval (AA) is a US Food and Drug Administration (FDA) expedited program intended to speed the approval of drugs and biologics that may demonstrate a meaningful advantage over available therapies for diseases that are serious or life-threatening.

Quick Search